Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001320254 | SCV001511034 | uncertain significance | Emery-Dreifuss muscular dystrophy 5, autosomal dominant | 2022-07-06 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. ClinVar contains an entry for this variant (Variation ID: 1020642). This variant has not been reported in the literature in individuals affected with SYNE2-related conditions. This variant is present in population databases (rs556962500, gnomAD 0.006%). This sequence change replaces glutamic acid, which is acidic and polar, with glycine, which is neutral and non-polar, at codon 4076 of the SYNE2 protein (p.Glu4076Gly). |
Ambry Genetics | RCV004671338 | SCV005165898 | uncertain significance | not specified | 2024-05-23 | criteria provided, single submitter | clinical testing | The c.12227A>G (p.E4076G) alteration is located in exon 62 (coding exon 61) of the SYNE2 gene. This alteration results from a A to G substitution at nucleotide position 12227, causing the glutamic acid (E) at amino acid position 4076 to be replaced by a glycine (G). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |